Market Overview

UPDATE: Jefferies Raises PT on Celgene Following Multiple Myeloma Survey


In a report published Thursday, Jefferies analyst Thomas Wei reiterated a Buy rating on Celgene Corporation (NASDAQ: CELG), and raised the price target from $114.00 to $140.00.

In the report, Wei noted, “We conducted a Medpanel survey of 59 U.S. physicians to determine opinions on current and future treatment options for multiple myeloma. Specifically, we found more favorable feedback on Pomalyst, as well as the potential for significant expansion of Revlimid frontline use. Based on our survey, we are raising our PT from $114 to $140.”

Celgene Corporation closed on Wednesday at $120.81.

Latest Ratings for CELG

Nov 2019DowngradesBuyHold
Nov 2019DowngradesOutperformNeutral
May 2019DowngradesOverweightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (CELG)

View Comments and Join the Discussion!

Latest Ratings

AMRXRaymond JamesDowngrades
CATStandpoint ResearchDowngrades
LULUWells FargoMaintains260.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Jefferies Raises PT on El Paso Electric Company on Lowered 2015 EPS Estimate

Morning Market Movers